Corticosteroid Dose and Pseudomonas Infection Risk

Introduction to Risk Factors

The American Thoracic Society recommends considering corticosteroid therapy at ≥10 mg of prednisone per day as a risk factor for Pseudomonas aeruginosa infection, with the threshold of ≥20 mg daily for ≥2 weeks representing high-risk dosing for opportunistic infections including Pseudomonas 1

In community-acquired pneumonia guidelines, the American College of Chest Physicians specifically identifies corticosteroid therapy at 10 mg of prednisone per day as a risk factor for P. aeruginosa 1
For COPD exacerbations, the European Respiratory Society considers oral steroid use >10 mg of prednisolone daily in the last 2 weeks as a risk factor for P. aeruginosa 2
The European Society of Clinical Microbiology and Infectious Diseases notes that use of ≥20 mg oral corticosteroid within 30 days is associated with increased risk of complications 3
Doses of 40 mg prednisolone or more carry even greater risks for postoperative infectious complications and anastomotic leaks 3

For patients with structural lung disease, the American Thoracic Society lists corticosteroid therapy at 10 mg of prednisone per day among risk factors for P. aeruginosa in pneumonia 1
In COPD patients, the European Respiratory Society recommends considering P. aeruginosa coverage if >10 mg of prednisolone daily in the last 2 weeks 2
The European Crohn's and Colitis Organisation notes that any corticosteroid use at time of IBD surgery increases risk of postoperative infectious complications 3

The American College of Chest Physicians recommends considering P. aeruginosa in the differential for respiratory infections for patients on 10-19 mg/day of prednisone 1, 2
The European Society of Clinical Microbiology and Infectious Diseases strongly recommends considering P. aeruginosa coverage in empiric therapy for respiratory infections for patients on ≥20 mg/day of prednisone for ≥2 weeks 1
The Gut journal notes that patients on ≥40 mg/day of prednisone are at the highest risk for infectious complications 3

The American Thoracic Society warns that recent antibiotic use (within 3 months) combined with corticosteroids further increases P. aeruginosa risk 2
The American Journal of Respiratory and Critical Care Medicine notes that broad-spectrum antibiotic therapy for 7 days in the past month plus corticosteroids creates particularly high risk 1
The European Society of Clinical Microbiology and Infectious Diseases recommends stopping or minimizing corticosteroid dose prior to elective procedures in surgical patients 3

The European Crohn's and Colitis Organisation recommends that corticosteroids at a total daily dose equivalent to ≥20 mg of prednisolone for ≥2 weeks significantly increase the risk of opportunistic infections, including pseudomonal infections 4, 5, 6
The use of corticosteroids, even at doses ≥10 mg/day of prednisolone, increases the relative risk for all infectious events (RR 1.30), while any dose increases the risk of opportunistic infections (RR 1.67) 5
The immunosuppressive effect of corticosteroids is dose-dependent, with higher doses associated with greater risk 7, 5

High-dose corticosteroids are defined as ≥20 mg/day of prednisolone for ≥2 weeks, which is associated with an increased risk of opportunistic infections 4, 5, 6
Patients receiving prolonged corticosteroid therapy at doses ≥20 mg/day for ≥2 weeks should be considered at high risk for opportunistic infections 6
The combination of corticosteroids with other immunomodulators substantially increases the risk (up to 14-fold with multiple immunomodulators) 4, 8

Advanced age is an independent risk factor that compounds the risk of opportunistic infections in patients on corticosteroids 5, 8
Malnutrition further increases the risk of opportunistic infections in patients on corticosteroids 4, 6

For patients requiring ≥20 mg/day of prednisolone for ≥2 weeks, consider monitoring for early signs of infection and minimizing steroid dose whenever possible 5, 6, 9
In perioperative settings, minimize corticosteroid use to reduce the risk of postoperative infectious complications 9
For patients with inflammatory bowel disease on high-dose steroids, combination with other immunomodulators should be carefully evaluated due to the multiplicative risk 4, 8